EUVIMEDObjevte EUVIMED
Crossref

Pharmacogenetic mechanism of cilostazol‐induced headaches: Splicing‐mediated loss of ABCC5 gene function

Sung Hee Lee, So Myoung Kim, Dong-Hwan Lee, Md Hasanuzzaman, Danbi Park, Md Intazur Rahaman, Seokil Lee, Yongchul Gu, Hye Won Kim, Wonhee Park, Hyunho Kim, Woo-Dae Bang and 10 more

British Journal of Pharmacology · 2026

DOI: 10.1111/bph.70597 ↗

At a glance

Journal article in British Journal of Pharmacology, 2026. Written by Sung Hee Lee and 21 co-authors. Institution: Department of Pharmacology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. Major MEDLINE topics: Cilostazol, ATP-Binding Cassette, Sub-Family C Proteins, Headache, Phosphodiesterase 3 Inhibitors. 51 references. Funded by: National Research Foundation of Korea (NRF), Ministry of Education.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background and Purpose Cilostazol, a phosphodiesterase 3 inhibitor, causes intolerable headaches in over one third of patients, frequently leading to treatment discontinuation. We investigated whether ABCC5 variant rs7636910 (NM_005688.4:c.1146A > G) protects against cilostazol‐induced headaches through altered cyclic nucleotide signalling. Experimental Approach Analysis included 101 healthy Korean volunteers from Phase 1 clinical trials, with independent replication in a multi‐ethnic cohort (n = 369) from the All of Us Research Program. Functional consequences of rs7636910 were evaluated through splicing analysis, expression studies, transport assays and cellular models examining cyclic nucleotide dynamics and vascular responses. Key Results G allele carriers showed a reduced risk of moderate‐to‐severe headaches (OR = 0.29, 95% CI 0.12–0.73), replicated in the multi‐ethnic cohort (OR = 0.26, dominant model). The variant disrupted canonical splicing, causing a 38‐bp deletion, premature termination, and nonsense‐mediated decay, reducing ABCC5 expression by more than 20% in blood and thyroid tissues. Cilostazol was not an MRP5 substrate, and pharmacokinetics were genotype‐independent. In ABCC5 ‐knockdown HCASMCs (Human Coronary Artery Smooth Muscle Cells), baseline cAMP was elevated tonically with paradoxical cGMP accumulation, whereas drug‐induced cAMP fold‐increases remained comparable to controls. Tonic cAMP elevation desensitised PKA, abolishing PDE3 inhibitor‐induced vascular relaxation despite elevated cAMP—a loss recapitulated by PKA inhibition in MRP5‐normal cells. Conclusion and Implications The rs7636910 variant reduces cilostazol‐induced headaches through a signalling‐based mechanism independent of drug pharmacokinetics, suggesting that transporter variants affecting endogenous substrate handling are as clinically important as drug‐metabolising enzyme polymorphisms. This variant represents a candidate pharmacogenetic biomarker for identifying cilostazol‐tolerant patients.

Subjects

MeSH terms (MEDLINE)

CilostazolATP-Binding Cassette, Sub-Family C ProteinsHeadachePhosphodiesterase 3 InhibitorsTetrazolesHumansMaleFemaleAdultPharmacogeneticsPolymorphism, Single NucleotideRNA Splicing

Author keywords

ABCC5cAMP/cGMP signallingcilostazolheadachepharmacogeneticssynonymous variant

Substances

CilostazolATP-Binding Cassette, Sub-Family C ProteinsABCC5 protein, humanPhosphodiesterase 3 InhibitorsTetrazoles

Authors and institutions

  • Department of Pharmacology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Department of Clinical Pharmacology, Hallym University Chuncheon Sacred Heart Hospital, Chuncheon, South Korea.
  • Department of Pharmacology, Hallym University College of Medicine, Chuncheon, South Korea.
  • Graduate Program of Industrial Pharmaceutical Science, Yonsei University, Incheon, South Korea.
  • Division of Medical Oncology, Department of Internal Medicine, St. Vincent's Hospital, Catholic University of Korea, Suwon, South Korea.
  • Division of Cardiology, Department of Internal Medicine, University of Ulsan College of Medicine, Gangneung Asan Hospital, Gangneung, South Korea.

ORCID profiles: Kyungsoo Park

Funding

  • National Research Foundation of Korea (NRF)
  • Ministry of Education

Cite

APA

Lee, S. H., Kim, S. M., Lee, D. H., Hasanuzzaman, M., Park, D., Rahaman, M. I., Lee, S., Gu, Y., Kim, H. W., Park, W., Kim, H., Bang, W. D., Park, J., Park, Y., Park, H. J., Lee, J., Cho, S. K., Park, K., Lee, M. G., …, & Kim, S. W. (2026). Pharmacogenetic mechanism of cilostazol‐induced headaches: Splicing‐mediated loss of ABCC5 gene function. British Journal of Pharmacology. https://doi.org/10.1111/bph.70597

Vancouver

Lee SH, Kim SM, Lee DH, Hasanuzzaman M, Park D, Rahaman MI, et al. Pharmacogenetic mechanism of cilostazol‐induced headaches: Splicing‐mediated loss of ABCC5 gene function. British Journal of Pharmacology. 2026. doi:10.1111/bph.70597

BibTeX
@article{Lee2026,
  author = {Lee, Sung Hee and Kim, So Myoung and Lee, Dong-Hwan and Hasanuzzaman, Md and Park, Danbi and Rahaman, Md Intazur and Lee, Seokil and Gu, Yongchul and Kim, Hye Won and Park, Wonhee and Kim, Hyunho and Bang, Woo-Dae and Park, Joonhee and Park, Yejin and Park, Hyun June and Lee, Jinu and Cho, Sung Kweon and Park, Kyungsoo and Lee, Min Goo and Lee, Ji Hyun and Lee, Eun-Jae and Kim, So Won},
  title = {Pharmacogenetic mechanism of cilostazol‐induced headaches: Splicing‐mediated loss of ABCC5 gene function},
  journal = {British Journal of Pharmacology},
  year = {2026},
  doi = {10.1111/bph.70597}
}
Start for free →